AU2022261654A1 - Modified polypeptides and uses thereof - Google Patents

Modified polypeptides and uses thereof Download PDF

Info

Publication number
AU2022261654A1
AU2022261654A1 AU2022261654A AU2022261654A AU2022261654A1 AU 2022261654 A1 AU2022261654 A1 AU 2022261654A1 AU 2022261654 A AU2022261654 A AU 2022261654A AU 2022261654 A AU2022261654 A AU 2022261654A AU 2022261654 A1 AU2022261654 A1 AU 2022261654A1
Authority
AU
Australia
Prior art keywords
cyclin
polypeptide
seq
nucleic acid
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022261654A
Other languages
English (en)
Other versions
AU2022261654A9 (en
Inventor
Roger Chung
Albert Lee
Luan LUU
Marco MORSCH
Stephanie RAYNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macquarie University
Original Assignee
Macquarie University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901193A external-priority patent/AU2021901193A0/en
Application filed by Macquarie University filed Critical Macquarie University
Publication of AU2022261654A1 publication Critical patent/AU2022261654A1/en
Publication of AU2022261654A9 publication Critical patent/AU2022261654A9/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/095Fusion polypeptide containing a localisation/targetting motif containing a nuclear export signal
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022261654A 2021-04-22 2022-04-22 Modified polypeptides and uses thereof Pending AU2022261654A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901193 2021-04-22
AU2021901193A AU2021901193A0 (en) 2021-04-22 Modified polypeptides and uses thereof
PCT/AU2022/050366 WO2022221922A1 (en) 2021-04-22 2022-04-22 Modified polypeptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2022261654A1 true AU2022261654A1 (en) 2023-11-09
AU2022261654A9 AU2022261654A9 (en) 2023-11-16

Family

ID=83723498

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022261654A Pending AU2022261654A1 (en) 2021-04-22 2022-04-22 Modified polypeptides and uses thereof

Country Status (7)

Country Link
US (1) US20240199713A1 (https=)
EP (1) EP4326340A4 (https=)
JP (1) JP2024515307A (https=)
CN (1) CN117241838A (https=)
AU (1) AU2022261654A1 (https=)
CA (1) CA3215808A1 (https=)
WO (1) WO2022221922A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007194A1 (en) * 2023-07-05 2025-01-09 Macquarie University Modulation of gene expression
WO2025081231A1 (en) * 2023-10-16 2025-04-24 Infensa Bioscience Pty Ltd Inhibitors and uses therefor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3535403A4 (en) * 2016-11-07 2020-08-12 MacQuarie University MODULATION OF PROTEIN ACCUMULATION AND ASSOCIATED USES
CA3126918A1 (en) * 2019-01-14 2020-07-23 President And Fellows Of Harvard College Methods and compositions for restoring stmn2 levels

Also Published As

Publication number Publication date
JP2024515307A (ja) 2024-04-08
US20240199713A1 (en) 2024-06-20
CN117241838A (zh) 2023-12-15
AU2022261654A9 (en) 2023-11-16
WO2022221922A1 (en) 2022-10-27
CA3215808A1 (en) 2022-10-27
EP4326340A4 (en) 2025-04-16
EP4326340A1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
JP7221275B2 (ja) Aavを送達するための組成物および方法
US10301366B2 (en) Compositions and methods for treatment of disorders related to CEP290
EP2844302A2 (en) Viral vectors for the treatment of retinal dystrophy
US20220362404A1 (en) Modulation of cellular viability
CN113710693B (zh) Dna结合结构域反式激活因子及其用途
CN116685329B (zh) 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途
US20240199713A1 (en) Modified polypeptides and uses thereof
US20240424039A1 (en) Aav-mediated gene transfer for retinopathy
US11866469B2 (en) DNA binding proteins and uses thereof
KR20210057720A (ko) Clrn1 관련된 청력 손실 및/또는 시력 손실의 치료 방법
US12161728B2 (en) Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F
WO2025007194A1 (en) Modulation of gene expression
US20260115325A1 (en) Methods and compositions for treating corneal wounds
AU2015202046B2 (en) A humanized model of membrane attack complex (mac) formation on murine retina and compositions, kits and methods for treatment of macular degeneration
EA049748B1 (ru) Виды генной терапии нейродегенеративных нарушений
JP2023513118A (ja) 遺伝子療法

Legal Events

Date Code Title Description
SREP Specification republished
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ CHUNG, ROGER; LEE, ALBERT; RAYNER, STEPHANIE; MORSCH, MARCO AND LUU, LUAN